---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-175567"
form_type: "8-K"
ticker: "TECX"
cik: "0001681087"
company_name: "Tectonic Therapeutic, Inc."
filed_at: "2025-08-07T23:59:59+00:00"
generated_at: "2026-05-17T17:47:31.239924+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Tectonic Therapeutic Q2 net loss $20M; cash $287.4M; TX45 PH-ILD Phase 2 planned 2026

## Summary
- Net loss of $20.0M in Q2 2025 vs $12.7M in Q2 2024; R&D expenses rose to $17.2M from $7.1M.
- Cash and cash equivalents $287.4M as of June 30, 2025; expected cash runway into Q4 2028.
- TX45 Phase 1b Part A results: 19% reduction in PCWP, 18.5% improvement in cardiac output, >30% PVR reduction in CpcPH.
- Part B of TX45 Phase 1b in PH-HFrEF enrollment completed; topline results expected early Q4 2025.
- New PH-ILD Phase 2 trial for TX45 to start in 2026; TX2100 Phase 1 expected Q1 2026.

## SEC filing metadata
- accession: 0001193125-25-175567
- form_type: 8-K
- ticker: TECX
- cik: 0001681087
- company_name: Tectonic Therapeutic, Inc.
- filed_at: 2025-08-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1681087/000119312525175567/0001193125-25-175567-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1681087/000119312525175567/d36621d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-175567
- JSON: https://secwatch.observer/filing/0001193125-25-175567.json
- Plain text: https://secwatch.observer/filing/0001193125-25-175567.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.